LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

Home・Aandelen Lijst・Quanterix Corp

Quanterix Corp

Open

SectorGezondheidszorg

2.98 -7.74

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.99

Max

3.24

Belangrijke statistieken
By Trading Economics
Inkomsten	5.6M -18M
Verkoop	-7.4M 36M
EPS	0.16
Winstmarge	-48.17
Werknemers	450
EBITDA	1.5M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+27.8% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	6.3M 165M
Vorige openingsprijs	10.72
Vorige sluitingsprijs	2.98

Nieuwssentiment

By Acuity

50%

161 / 344 Rangschikking in Healthcare

Quanterix Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jun 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Belangrijke Marktbewegers

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Marktinformatie

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Acquisities, Fusies, Overnames

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Marktinformatie

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Marktinformatie

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Marktinformatie

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Marktinformatie

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Marktinformatie

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Marktinformatie

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Acquisities, Fusies, Overnames

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Marktinformatie

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Marktinformatie

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Marktinformatie

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Vergelijking

Prijswijziging

Quanterix Corp Prognose

Koersdoel

By TipRanks

27.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD 27.8%

Hoogste 4 USD

Laagste 4 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Quanterix Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Quanterix Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

161 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.